Examkin

Question

Difficulty: MediumPharmacologic Interventions

A 61-year-old man presents to the primary care clinic for a follow-up visit. Three weeks ago, he was diagnosed with active pulmonary tuberculosis and started on a regimen of rifampin, isoniazid, pyrazinamide, and ethambutol. Two days ago, he presented to an urgent care clinic with palpitations and was diagnosed with new-onset atrial fibrillation. His past medical history is significant for hypertension, type 2 diabetes mellitus, and heart failure with preserved ejection fraction. Based on a CHA2DS2-VASc score of 4, the urgent care physician initiated apixaban and metoprolol. The patient reports that his palpitations have resolved, and he has not experienced any bleeding, bruising, or neurologic symptoms. His temperature is 37.1°C (98.8°F), blood pressure is 126/78 mmHg, and pulse is 76/min and irregularly irregular. Cardiopulmonary examination is otherwise unremarkable. Which of the following is the most appropriate modification to this patient's pharmacotherapy?

  1. A
    Continue the current regimen with close clinical monitoring
  2. B
    Change apixaban to rivaroxaban
  3. Change apixaban to warfarinAnswer
  4. D
    Increase the dose of apixaban
  5. E
    Discontinue apixaban and initiate aspirin therapy

Answer

Change apixaban to warfarin
The correct answer is to switch the direct oral anticoagulant (DOAC) to a vitamin K antagonist. The patient has a high risk of thromboembolism from atrial fibrillation (CHA2DS2-VASc score of 4) and requires systemic anticoagulation. He was recently started on apixaban, a DOAC. However, he is also taking rifampin for active pulmonary tuberculosis. Rifampin is a potent inducer of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Apixaban is a substrate for both CYP3A4 and P-gp. Co-administration of strong CYP3A4 and P-gp inducers like rifampin significantly decreases the plasma concentration of apixaban, thereby compromising its efficacy and increasing the risk of stroke. As a result, the concurrent use of apixaban and rifampin is contraindicated. To provide effective anticoagulation, the patient should be switched to a medication whose efficacy can be monitored and dose-adjusted. Warfarin is metabolized by CYP enzymes, and its metabolism is also induced by rifampin. However, the dose of warfarin can be easily titrated to achieve a therapeutic International Normalized Ratio (INR), making it the preferred oral anticoagulant for patients requiring concurrent rifampin therapy.

Step-by-Step Solution

1
Analyze the patient's current medication list and new diagnosis.
The patient is taking rifampin for tuberculosis and apixaban for new-onset atrial fibrillation.
Identifying concurrent medications is essential for preventing adverse drug events.
2
Identify potential pharmacokinetic interactions between the medications.
Rifampin is a strong inducer of CYP3A4 and P-glycoprotein (P-gp), while apixaban is a substrate for both.
Strong inducers increase the clearance of substrates, leading to subtherapeutic drug levels.
3
Determine the most appropriate alternative therapy for stroke prevention.
Warfarin should be selected over DOACs because its dose can be titrated and monitored using the INR.
Unlike DOACs, warfarin therapy allows for objective measurement of the anticoagulant effect despite concurrent enzyme induction.

Key Concept

Management of pharmacokinetic interactions involving direct oral anticoagulants (DOACs) and potent CYP3A4/P-gp inducers.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic